Head-down position and abdominal gas effects on optic nerve sheath size during robotic prostate removal

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study will measure optic nerve sheath diameter by ocular ultrasound at predefined time points before, during, and after surgery in patients undergoing robot-assisted laparoscopic radical prostatectomy and in a comparison group undergoing open radical prostatectomy. Intraoperative hemodynamic and respiratory variables, intra-abdominal pressure, blood loss, fluid administration, and surgery duration will be recorded to correlate physiological changes with optic nerve sheath measurements. The aim is to determine whether pneumoperitoneum and steep Trendelenburg positioning produce measurable increases in optic nerve sheath diameter and whether those changes relate to other intraoperative parameters. Data will be collected at a single center and analyzed to compare the two surgical approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* ASA physical status I-III
* Patients scheduled for robot-assisted laparoscopic radical prostatectomy or open radical prostatectomy under general anesthesia
* Written informed consent obtained

Exclusion Criteria:

* History of intracranial surgery or intracranial lesion
* Known ocular disease (glaucoma, retinal detachment, diabetic retinopathy, previous ocular surgery, etc.)
* Intraocular pressure greater than 30 mmHg
* Refusal to participate in the study

Where it's running

• Ege University Faculty of Medicine Hospital
  Izmir, İzmir, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: Nursen Karaca, Md — Ege University
• Study coordinator: Nursen Karaca, MD
• Email: dr.nursenkaraca@hotmail.com
• Phone: +902323902142

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.